300685.SZ - Amoy Diagnostics Co., Ltd.

Shenzhen - Shenzhen Delayed price. Currency in CNY
-0.07 (-0.26%)
At close: 03:04PM CST
Stock chart is not supported by your current browser
Previous close26.48
Bid26.41 x 0
Ask26.48 x 0
Day's range26.11 - 26.65
52-week range20.68 - 35.24
Avg. volume1,734,017
Market cap10.515B
Beta (5Y monthly)0.68
PE ratio (TTM)38.84
EPS (TTM)0.68
Earnings date22 Apr 2022 - 25 Apr 2022
Forward dividend & yield0.14 (0.53%)
Ex-dividend date23 May 2023
1y target est38.34
  • GlobeNewswire

    AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC

    TOKYO and XIAMEN, China, March 27, 2023 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg and 80 mg. The AmoyDx® PLC Panel is based on polym

  • PR Newswire

    Qiming's Portfolio Company InventisBio Lists on STAR Market

    Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion.

  • PR Newswire

    Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion

    Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million).